Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

37.34
+0.53001.44%
Post-market: 37.21-0.1287-0.34%19:53 EDT
Volume:4.30M
Turnover:160.85M
Market Cap:43.50B
PE:62.23
High:37.75
Open:36.79
Low:36.65
Close:36.81
52wk High:37.83
52wk Low:17.82
Shares:1.17B
Float Shares:1.09B
Volume Ratio:0.87
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.61
PE(LYR):30.86

Loading ...

Teva Expands European Biosimilars Portfolio With Launch of Ahzantive® (Aflibercept) Biosimilar to Eylea®

THOMSON REUTERS
·
Jun 04

Alvotech, Teva Resubmit 2 Proposed Biosimilar Applications to the FDA for Retinal Treatment

MT Newswires Live
·
Jun 04

Update: UroGen Settles Patent Dispute With Teva; Generic Jelmyto Delayed Until 2030

MT Newswires Live
·
Jun 02

Piper Sandler Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Jun 01

Teva Shareholders Back Board, Executive Pay and Auditor

TIPRANKS
·
May 29

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Thermo Fisher (TMO) and Eli Lilly & Co (LLY)

TIPRANKS
·
May 27

Teva announces EMA acceptance of MAA for olanzapine long-acting injectable

TIPRANKS
·
May 22

Teva Study Finds Only 23% of Younger Adults With Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed With TD Despite Widespread Impact

THOMSON REUTERS
·
May 18

Teva put volume heavy and directionally bearish

TIPRANKS
·
May 15

Teva, Upstart, Bloom, Corning, Seagate Insider Shock

TIPRANKS
·
May 09

Top Teva Executives Cash Out in Major Insider Stock Moves

TIPRANKS
·
May 08

A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong Q1 2026 And Biopharma Pipeline Progress

Simply Wall St.
·
May 07

Teva Pharmaceuticals Is Maintained at Overweight by Barclays

Dow Jones
·
May 06

Teva Earnings Call Highlights Innovative-Driven Margin Upswing

TIPRANKS
·
May 06

Is It Too Late To Reassess Teva Pharmaceutical Industries (TEVA) After Its Strong Multi Year Rally?

Simply Wall St.
·
May 06

Top Teva Executives Quietly Offload Major Stock Stakes

TIPRANKS
·
May 05

Leader Capital Markets Remains a Buy on Teva (TEVA)

TIPRANKS
·
May 01

Teva Pharmaceuticals Is Maintained at Buy by Truist Securities

Dow Jones
·
Apr 30

Truist Raises Price Target on Teva Pharmaceutical Industries to $45 From $42, Keeps Buy Rating

MT Newswires Live
·
Apr 30

Piper Sandler Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Apr 30